28,246 Shares in Medtronic PLC $MDT Acquired by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. acquired a new position in Medtronic PLC (NYSE:MDT) during the third quarter, HoldingsChannel reports. The fund acquired 28,246 shares of the medical technology company’s stock, valued at approximately $2,690,000.

A number of other institutional investors have also made changes to their positions in the business. Corundum Trust Company INC acquired a new stake in Medtronic in the 3rd quarter valued at about $27,000. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the second quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic in the 3rd quarter worth approximately $33,000. Tripletail Wealth Management LLC bought a new position in Medtronic in the 3rd quarter valued at $34,000. Finally, Clean Yield Group increased its stake in shares of Medtronic by 265.7% in the 3rd quarter. Clean Yield Group now owns 384 shares of the medical technology company’s stock valued at $37,000 after buying an additional 279 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Trading Down 0.6%

Shares of NYSE:MDT opened at $96.22 on Tuesday. The firm has a market cap of $123.35 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 2.55 and a beta of 0.71. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company’s fifty day simple moving average is $99.08 and its 200 day simple moving average is $94.99. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s payout ratio is presently 76.55%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MDT shares. JPMorgan Chase & Co. upped their price target on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Wells Fargo & Company upped their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Sanford C. Bernstein upped their price objective on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).